Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Recinnamine
2. Reserpinene
3. Trimethoxycinnamoyl Methyl Reserpate
4. Methyl (1r,15s,17r,18r,19s,20s)-6,18-dimethoxy-17-[3-(3,4,5-trimethoxyphenyl)prop-2-enoyloxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
5. Ncgc00016787-01
6. 3,4,5-trimethoxycinnamoyl Methyl Reserpate
7. Cas-24815-24-5
8. Prestwick0_000568
9. Prestwick1_000568
10. Dsstox_cid_3554
11. Dsstox_rid_77079
12. Dsstox_gsid_23554
13. Spbio_002575
14. Chembl3182071
15. Tox21_110611
16. Db01180
17. Q27164665
18. (1r,15s,17r,18r,19s,20s)-6,18-dimethoxy-17-[1-oxo-3-(3,4,5-trimethoxyphenyl)prop-2-enoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic Acid Methyl Ester
| Molecular Weight | 634.7 g/mol |
|---|---|
| Molecular Formula | C35H42N2O9 |
| XLogP3 | 4.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 11 |
| Exact Mass | 634.28903092 g/mol |
| Monoisotopic Mass | 634.28903092 g/mol |
| Topological Polar Surface Area | 118 Ų |
| Heavy Atom Count | 46 |
| Formal Charge | 0 |
| Complexity | 1080 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 1 |
| Covalently Bonded Unit Count | 1 |
For the treatment of hypertension.
Used to treat hypertension. Rescinnamine inhibits angiotensin-converting enzyme. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex and general vasoconstriction, both of which lead to increases vascular resistance. By inhibiting angiotensin II, aldosterone reabsorption is decreased as well as vasoconstriction. This combined effect serves to decrease blood pressure.
Rescinnamine Binds to and inhibits the angiotensin converting enzyme. Rescinnamine competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion.
ABOUT THIS PAGE
A Rescinnamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rescinnamine, including repackagers and relabelers. The FDA regulates Rescinnamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rescinnamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rescinnamine supplier is an individual or a company that provides Rescinnamine active pharmaceutical ingredient (API) or Rescinnamine finished formulations upon request. The Rescinnamine suppliers may include Rescinnamine API manufacturers, exporters, distributors and traders.
click here to find a list of Rescinnamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rescinnamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Rescinnamine active pharmaceutical ingredient (API) in detail. Different forms of Rescinnamine DMFs exist exist since differing nations have different regulations, such as Rescinnamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rescinnamine DMF submitted to regulatory agencies in the US is known as a USDMF. Rescinnamine USDMF includes data on Rescinnamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rescinnamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rescinnamine suppliers with USDMF on PharmaCompass.
Rescinnamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rescinnamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rescinnamine GMP manufacturer or Rescinnamine GMP API supplier for your needs.
A Rescinnamine CoA (Certificate of Analysis) is a formal document that attests to Rescinnamine's compliance with Rescinnamine specifications and serves as a tool for batch-level quality control.
Rescinnamine CoA mostly includes findings from lab analyses of a specific batch. For each Rescinnamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rescinnamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Rescinnamine EP), Rescinnamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rescinnamine USP).
LOOKING FOR A SUPPLIER?
